Francia Cabrera y Equipo

7/21/2019 Francia Cabrera y Equipo

1/39

SERVICIO FARMACUTICO LAS 24 HORAS

ANDREA ESCOBAR DORADO

FRANCY JOHANA CABRERA RIVERA

LEIDY ESCOBAR YELA.

ASESORA

LUZ HELENA HERNANDEZ CALDERON

LNEA DE GESTIN ADMINISTRATIVA Y COMERCIAL.

UNIVERSIDAD AUTNOMA DE BUCARAMANGA

EDUPOL

2014


2/39

TABLA DE CONTENIDO

N DETALLE P!GINA

INTRODUCCIN 6

1.0 TITULO DEL PROYECTO 7

1.1 SITUACIN DEL PROBLEMA 8

1.2 JUSTIFICACIN 11

1.3 OBJETIVOS GENERAL Y ESPECFICOS 12

2.0

3.0

3.1 3.1.1

3.2

3.3

.0

!.0

6.06.16.26.3

7.07.17.2

7.3

8.0

".0

10

10.1

MARCO TERICO Y ESTADO DEL ARTE

DISE#O METODOLOGICO

CLASE DE INVESTIGACIONENFO$UE DE LA INVESTIGACION

%IPOTESIS

VARIABLES

POBLACION Y MUESTRA

TECNICA

TALENTO %UMANORECURSOS %UMANOSRECURSOS MATERIALESRECURSOS FINACIEROS

PRESUPUESTO RECURSOSESTADO FINACIERO

PLAN DE COMPRAS

CRONO GRAMA

DIVULGACION

DISE#O METODOLOGICO Y ASPECTOSESPECIFICOSTABULACION GRAFICACION Y ANALISIS DERESULTADOS.

13

16

17

18

1"

20

21

22

23

2


3/39

1111.111.2

ESTUDIO DEL MERCADOMARCO LEGALMARCO ADMINISTRATIVO

BIBLIOGRAFIA

GLOSARIO

282831

3!

36


4/39

LISTA DE TABLAS

P"#$% &"' ()(*&"' + &+' (+,&+'PAGINA

TABLA 1TABLA 2TABLA 3TABLA TABLA !TABLA 6TABLA 7TABLA 8TABLA "

181"1"20212262728

TABLA 10 2"


5/39

LISTA DE GRAFICOS

P"#$% &"' ()(*&"' + &"' -%/"' PAGINAGRAFICA 1GRAFICA 2GRAFICA 3GRAFICA GRAFICA !GRAFICA 6

22!26272833


6/39

INTRODUCCION.

L&' (')*+,(-/()&' */*-4)-&' (')5 (('()*&' & ,*' '))4-&('

( &( '( (')* '(-&' ( *)(-9 */*-4)-*. T(( 4-&(' (

*)(-9 *, *-()(: /(*)( ,* (')*-9 ( 4 *(-4*& '(-& */*-4)-&: &

( *+-*-9: ( *-4(& -& ,*' +4(*' 5-)-*' ( /*4*-)4*: ( ,&'

/(-*/()&' ; &4-)&' +&&*' (, =*.

S (/+*?& >*; *,?& /5' )*, ** ,* /'/* -&/4* &*&' '4(')* * *)((


7/39

->& (-*-(: & ,& )*)& & *')* (, =* '?4()( ; ('(* * & ( >*-(,&.

E, )(/* '&+( '(-& */*-4)-& * ,*' 2 >&*': (/&' *-( *)( ( (')( &;(-)& ;*


8/39

TITULO DEL PROYECTO

CDIGO DEL PROYECTO GAC10820012

NOMBRE DEL PROYECTO SERVICIO FARMACUTICO LAS 2 %ORAS.

LUGAR DONDE SE DESARROLLARA EL PROYECTO SAMANIEGO NARI#O


9/39

SITUACION DEL PROBLEMA

L* &+,(/5)-* (')()( ( (, /4-& ( S*/*(?& (' ,* *,)* ( 4*

&?4(=* &')*, L&(-)* V,,(?*' ( S*)&'H ' (/+*?& ( /4->*' &&)4*(' (')(

*-()('


10/39

E, )& ( &+,*-9 *, -4*, '( ?( (')( &;(-)&: (')5 -&-()*& ( ,*'

12000 */,*' *(-)**' & ,* & -&'(-4-9 ( /(-*/()&' ( >&*&' 4(*

( ,&' >*+)4*,(' ; ;* (')()(': *(/5' ( '4/*,( &*'


11/39

JUSTIFICACION

E')( &;(-)& '( (*,* -& (, ( /(&* ,* -*,* (, '(-&*/*-4)-& ( (, /4-& ( S*/*(?&: ( &/*


12/39

OBJETIVOS

OBJETIVO GENERAL

A4/()* (, *--('& ( &/* /(*)* ; -(-** * +((' ; '(-&'

*/*-4)-&' ( -*,* 4*)( ,*' 2 >&*' ( (, M4-& ( S*/*(?& N*@&.

OBJETIVOS ESPECIFICOS

B((-* *, /4-& ( S*/*(?& -& 4 (')*+,(-/()& */*-4)-& (')& *

*)((,& ( -4*,


13/39

1. MARCO TERICO Y ESTADO DEL ARTE

L* -*,* ( ,&' '(-&' ( '*,4 ( C&,&/+* -** =* (-*( /5': ('( * ,*'

/(&*' ( ,*' &/*': (-()&': ; ,(;(' &' '(-&' '( >* & -(/()*& -& (, *'&

(, )(/&.

D( *-4(& * ,* /'9 (, C&/&()( ( F*/*-&)(** FT (' &&-&*

'(?4* * ,&' *-()(' ; '4' */,*(': /(*)( (, *&;& )--& ('(-*,*&

( -4*)& *, &-('& ( ?(')9 ( ,* *)(-9 )(?*, 5/*-& )(*4)-* /*(&

( ,&' /(-*/()&' ( '4/&' /-&' ( ,& ((()( * -&/*: *,/*-(*/()&:

')+4-9: */')*-9: (**-9 ; -&)&, ( &/* &&)4*: (-()( ;

*(-4** '(? ('--9 /-* ; (-('*&' ** -&)+4 * ,* &'9 (

*)(-9 )(?*, -& -*,*: -*,(: >4/*'/&: (* & )&/*&

( /*(* ((()( 4 *(, )*, ( ,*' -&/4*(' * (, /4*,: ,*

/(* +&)-* (* &(* (, /-& ('*@&, A,(*& G*')(,+&& ( 1871:

4+-** ( ,* ,** /*;& ( S*)* F( ( B&?&)5 >&; ,** ( B&,=*.J4*

V(,(: 2010

E, '(-& */*-4)-& ( ?((*, )(( -&/& &+()&' /&*,(' ,*

&/&-9: ,* ((-9: (, '4/')& ; ,* *)(-9 */*-4)-* R('&,4-9 103

(2007: & ,& )*)& (' ,&


14/39

E C&,&/+* '( >* -)-*& '&+( ,&' '(-&' ( (')*-9 ( '*,4: ( ,&'

* *4/()*& ,* '*)'*--9 -&/4)** & )(( /*;&

-*/+& ( (')* /*)(*: ,&' -&')&' >* **& '?-*)(/()(: ; *4 '( ('(*& 4 '(-& ( -*,* ; /5' >4/*&.A&)(' (+*,(' ( ,&' ('()(': 201.

A)(& * ,&' *@&' 30 & (')=* ( (, /4-& 4 ()(/*& ')& *'

*&/**' (, *@& 1"30: (&/** ,* B&)-* (, '(@& A4?4')& N. E*&:

B+,&)(-* +,-* C&-4;&': S*/*(?& 201


15/39

/5' ( ,&' *@&' ( 1"3! ,* -4*, (' */')** & ,* '(@&* R&')* L(9 (

V*?*': (& -& -**-)(=')-*' '/,*(' * ,* /(*: *@&' /5' )*( 4)& * ,*

/&(*-9 ; ,* ()** ( (, 4(& '?,& '( -(/()* ,* -(*-9 ( */*-*'( (, /4-&: (*& *)5' ,*' +&)-*': (& ' (/+*?& *4*;* -&()& ( */*-*' *&)*&

-** 4& ( ,&' (-()&' ; ,(;(' &/4,**' ** /(&* (, '(-&: ,*

-&&/* (' 4 (&/*& -&/ ( )&&' ,&' )(/&' )*)& * (, ?((*,

-&/& (, -*'& *)-4,* ( 4(')& S*/*(?&: -**-)(*-9


16/39

3.0 DISEO ETODOLOGICO

3.1 CLASE DE INVESTIGACIN

3.1.1 E&&*' :( (, M4-& ( S*/*(?& ( -&,*+&*-9

-& *,?4*' ('&*': +4'-*& ,* *)-*-9 ( ,&' >*+)*)(' ( '(-)&

; )&*' *&*' '&+,(' ** ,*'

(-('*(' ( ,&' >*+)*)(': >* -& ( ,* (-('*


17/39

4.0 POBLACIN Y MUESTRA

POBLACIN L* &+,*-9 ( (, ('()( (')4& (')* -&&/** & ,*

-&/4* (, '(-)& (, /4-& ( S*/*(?&: -&/(* & 308""

( (, -*'-& 4+*& ('&*' -4;*' (*(' &'-,* ()( 1! ; 80 *@&' (

(*. MUESTRA L* /4(')* (,(?* ** (, ('()( (')4& (')5 -&&/**

& (, 100 >*+)*)(' * '& (-4(')*&'. C9/& ()(/*& (')*

/4(')*: +*&


18/39

6.0 TALENTO HUMANO

6.1 RECURSOS6.1. RECURSOS %UMANOSK R(?()( ( F*/*-*. 6.2. RECURSOS MATERIALESK D&?4(=*: /(-*/()&': (')*)(':

(


19/39

7.1 RECURSOSL* +*'( -*, (, (?&-& '(* 60.000.000 ,&' -4*,(' '& ,* +*'(


20/39

GASTOS DE MEDICAMENTOS $ ,1.6:0.000SERISIOS PUBLICOS ; )!!"a" $ 1.300.000TOTAL EGRESOS $ 60.000.000

TOTAL INGRESOS $

60.000.000

7.3 PLAN DE COMPRAS

D()& ( 4(')* &4(')* ( -&/* ** (, -& ( 4(')* &?4(=* )((/&'

4 ('44(')& ( 1.6"0.000 )((/&' ,&' '?4()(' -&/*' * 4(')&'

&((&(' -()-*&' & ,&' (()(' -&)&,(' ( -*,* ; '(-&.

Tabla 4

##%#n& 'a&( &a(&a+


21/39


22/39

9.0 CRONOGRAMA

Tabla 5

NOMBRE DE ACTIVIDADDURACION COMIEZO FIN NOMBRE DE LOS ENCARGADOS

COMFORMACION DELGRUPO DE INVESTIGACION 1 /('

((& (+10ANDREA ESCOBAR:JO%ANA CABRERA:LEIDY ESCOBAR

FIJACION DE ACTIVIDADES 1! =*'10 (/*&

2! (/*& ANDREA ESCOBAR

DISE#O DE FORMULACIONDE PREGUNTOS ! =*'

2! (/*&

01*+JO%ANA CABRERA:LEIDY ESCOBAR

VALIDACION DEFORMULACION DEPROYECTOS 20 =*'

01*+21 (*+,

JO%ANA CABRERA:APLICACIN DEPREGUNTAS 2! =*'

22 (*+,

22 /*;& LEIDY ESCOBAR

ANALISIS DE RESULTADOSDE PREGUTAS 10 =*' 22/*; 024 ANDREA ESCOBAR:JO%ANA CABRERA:LEIDY ESCOBAR

ADECUACION DE LOCAL 20 DIAS024

2! DEJUNIO ANDREA ESCOBAR:LEIDY ESCOBAR

COMPRA DE 1! DIAS 204 014, JO%ANA CABRERA


23/39

MEDICAMENTOS


24/39

P"% /+:"% %$:'+% &+' /$;+' 8$& %"#"-%+


25/39

10 DISEO METODOLGICO Y ASPECTOS ESPECFICOS

10.1 TABULACION Y GRAFICACION Y ANALISIS DE RESULTADOS

D( *-4(& * 4(')& )& ( (')4& *,-*/&' ,* '?4()( (-4(')*.

1. A U')( ,( ?4')*=* 4* &?4(=* -& '(-& 2 >&*'

Tabla 6. Poner ttulo

SI NOHOMBRES 10 :0

SI NO

MUJERES 13 8

HOMBRES MUJERES

0

20

,0

60

80

100

10

013

90

0

87

HA USTED LE GUSTARIA UNA DROGERIA CON SERVICIO 24 HORAS

SI NO

.&$a!&n #n)#+a"a

HABITANTES

Ilustracin 1

Poner la grfica en porcentajes y unir la informacin de hombres y de mujeres, es indistinto el

gnero. Tener en cuenta esta observacin para las dems preguntas


26/39

E)( ,&' >&/+(' (-4(')*&' ('&(& ( ; (, 3! ( ,*&+,*-9 (-4(')** ('&( &')*, '&,& * ,&' /(-*/()&' *')*


27/39

E)( ,&' >&/+(' (-4(')*&' ('&(& *;

&?4(=*' *;

(& ( &-*'&(' (')* /*, '(-& ; '& /5' -&')&'&' ; (, 87

('&( &(a+

SI NO

>a!an#+ #n)#+a"&+

>a!an#+

Ilustracin 3

E)( ,&' >&/+(' (, 88 ( ,&' (-4(')*&' ('&(&


28/39

& '*+( -45& '( 4(( ((/*. E, 12 ( ,* &+,*-9 (-4(')** ('&(

&/+(' (, 2! ( ,&' (-4(')*&' ('&(&


29/39

5. S U'($8 /*$%+ *# &$#($ ?%"&/+(' (-4(')*&' 8" ( ,&' (-4(')*&' ('&(&


30/39

A*,,*?&' (, (')4& ( /(-*&

11 ESTUDIO DE MERCADO

E 4(')& /4-& (' /4; *-)+,( ,* -(*-9 ( (')* &?4(=* ;*


31/39

'(--&*,(' & L&-*,(' ( S*,4 & ,*' ()*(' *?* '4' (-(': 23

*4)&*-9 ; *&+*-9 ** '4 *()4* & )*',*& ()& (, )()&&

*-&*,. ARTICULO TERCEROK P** ((-)&' ( &+)(( ,* *4)&*-9 **,* ')*,*-9 ( 4* D&?4(=*: (, )(('*& (+(5 ('()* & ('-)&

'&,-)4 * ,* &-* ( C&)&, ( M(-*/()&': *-&/*@*& -&?-&': '*)*&':

(,-)-*': 5(* *(-4** 4-* (& * ()( 20 /()&' -4**&':

*-,* ( *--('& *-)+,* ( (')* (, '(-& &-)4&: (((-*; '(**-9 (?,*/()** ( &)* 4 &)*' D&?4(=*'. ARTICULO $UINTOK

P** ,* *&+*-9 ( *()4* & )*',*& ( D&?4(=*' & F*/*-*'

D&?4(=*' ( )&& (, )()&& *-&*,: (+(5 (') 4* ')*-* /=/*

( -()& --4()* 1!0 /()&' ,(*,(' * ,* (&* ()( ,* &?4(=*

'&,-)*)( =* &?4(=* /*' -(-**.

2 LEY NACIONAL DE LA ACTIVIDAD FARMACUTICA A)=-4,& 7 L*'

'&'-&(' ( (')( )=)4,& '& ( *,-*-9 * ,* *-)* */*-4)-* ()&& (, 5/+)& *-&*,: ' (4-& ( ,* *,( ( ,*': '&'-&('

?()(' ( -** 4'--9. A)=-4,& " L* &?4(=* (+(5 (-,** 4

')&- /=/& ** ?**)* (, *+*')(-/()& ( -*'& ( -*)5')&( ; & '(

&5 (* ('*+*')(-& (, '')(/* */*-4)-&: (+(& )&/*'( ,*'

/(*' (-('**' * )*, . A)=-4,& 10 E ,*' &?4(=*': (, 5/*-& (+(

(')* ,&' '?4()(' '(-&' +5'-&' * ,* &+,*-9. * L* &'9:

-4')&*: -&'(*-9 ; '('*-9 ( ,&' /(-*/()&' ; (/5'

&4-)&' ( '4 -4/+(-* &('&*,. + L* ?,*-*: -&)&,: ;&

-4')&* ( ,*' (-()*' /-*' '('**'. - S(-&' ( *)(-9

*/*-4)-* ** *


32/39

*4)&*& (+*/()( & (')* ,(; ; >*+,)*& & (, M')(& ( S*,4 ;

(((-*': -&/& D(--9 ( F*/*-*: -&/& (, ANMAT: ** ,*

'('*: ')+4-9 ; *+*')(-/()& ( )&&' ,&' &4-)&':/(-*/()&' ; *--('&&': *4)&*&' & S*,4 P+,-* ; ANMAT: ** '(

((& ( */*-*'. A)=-4,& 12 T&*' ,*' */*-*' *+,)*-9 (+( -&)* -& 4 ,&-*,: *+,)*-9: *4')*& * ,*'

-&-&(' *+,)*-9. 26

A)=-4,& 18 L*' */*-*' (+( )(( 4 &('&*, */*-4)-&

('&'*+,( -&/& (-)& )--& 4*)( (, >&*& ( *)(-9 *, +,-&. E,

(-)& )--& (+(5 -&/& /=/& (/*(-( ( ,* */*-* * '4 -*?&:

4*)( &->& 8 >&*' 4*)( (, >&*& ( *)(-9 *, +,-&. A)=-4,& 1"

L&' (*'(' (')*&' * ,* -&'(*-9 ( '4')*-*' (/,(**' ( ,*'*/*-*': *'= -&/& ,&' ( *, +,-&: (+( (')* -,**/()(

&)4,*&' ( &/* *-&*,: & 4(& >*-('( *'*4*': '&+

&)4,*-&(': (/(*'. A)=-4,& 22 E ,*' &?4(=*' (+( /*)(('(

*-)4*,*&' ,&' ,+&' *+,)*-9 ; 4-&*/()&. A)=-4,& 26 S9,& 4(( *4)&*'( ,*

')*,*-9 ( &?4(=*' -4*& '4 &(* '(*K * D(, &('&*,

*/*-4)-&. 27 + D( -4*,*+,)** **

-&)*)*. A)=-4,& 28 T&* &?4(=* (+( '( ?* & 4 */*-4)-& *

-*?&. A)=-4,& 2" E, (-)& )--& ( 4* */*-* (+(K * E>+ '4

)=)4,& &('&*, -&/& (?()( & *4,* ( */*-*. - T(( 4 ((/,* (

,* ('()( ,(; ; '4 (?,*/()*-9. T(( 4 ,*& (, ,&-*, *4)&*& &

,* *4)&* 4'--&*, -&/()()( ; ,*' -&')*-*' ( >*+,)*-9 (,

(')*+,(-/()&. ( P((


33/39

/('&' ( ?((*, ?4( '4 &/+( ; '4 )=)4,& (+(& -&'?*'( (

')&' ,)/&' ,* (&/*-9 ( ,* ()* &()** ( ,* */*-* ; '4

&/-,&. ? P(( ; (-* *+,)*-9 (* ( ,*

*4)&* -&/()()(. A)=-4,& ! L*' &?4(=*' (+( -&)* -& 4*(--9 )--*: * -*?& ( 4 */*-4)-& /*)-4,*&.

$4 )& ( (/('* * * -(*: *%)8+ 8$ &+ $


34/39

((()(/()( ( ,*' *-)*(' (')*' ( '4 &+()& '&-*,. P**

((-)&' )+4)*&': ,* '&-(* & *--&(' '/,-** '( (?5 & ,*'

(?,*' *,-*+,(' * ,*' '&-(*(' *9/*'. L* '&-(* & *--&(''/,-** '( -(*5 /(*)( -&)*)& & *-)& 4,*)(*,


35/39

& /*;& ; & /(& ( &4-)&' *)4')*' ( (')*+,(-/()&'

('(-*,*&'. R('&'*+,* S&,** I-,4'&: '( (')*-*


36/39

?*': *?4* ; (,(-)-*: ())&(' * 4),* )((& ( -4()* ,* -,*'( (

/*)(*,(' 4'*&' ; -&/(-*,*&'. A '4 ( -** ,*' &/*' (

'(?4* 4')*,


37/39

()& ( ,* &?**-9: * ( *-,)* (, ,&?& ( ,&' &+()&' (,

&;(-)&: (')*+,(-(& '')(/*' ( -&)&, ; &-('*/()&' ))K('.',('>*(.()M(,'*B4)-*-*,*('*,4(

-&,&/+*16723108

J4* A(' V(,(. 20 ( S()(/+( ( 2010. O=?((' ( ,* */*-*. . O+)(&

(, 13 ( &-)4+( ( 201 ( >))K('.',('>*(.()J*('*,&?(('(,**/*-*

F*/*-*. O+)(& (, 1 ( O-)4+( ( 201 (

>))K('.(*.&?F*/*-*

R('&,4-9 103 ( 2007. O+)(& (, 1 ( O-)4+( ( 201 (

>))'K./'*,4.?&.-&N&/*)*XN4(&RESOLUCION2010320DE

202007.

>))K,(?',*-&*/*-(4)-*.+,&?'&).-&/20080!(')*+,(-/()&'

*/*-(4)-&'.>)/,
http://es.slideshare.net/MelisaBuritica/calidad-de-salud-en-colombia-16723108http://es.slideshare.net/MelisaBuritica/calidad-de-salud-en-colombia-16723108http://es.slideshare.net/Javesal/origenes-de-lafarmaciahttp://es.wikipedia.org/wiki/Farmaciahttps://www.minsalud.gov.co/Normatividad_Nuevo/RESOLUCION%201403%20DE%202007.pdfhttps://www.minsalud.gov.co/Normatividad_Nuevo/RESOLUCION%201403%20DE%202007.pdfhttp://legislacionfarmaceutica.blogspot.com/2008/05/establecimientos-farmaceuticos.htmlhttp://legislacionfarmaceutica.blogspot.com/2008/05/establecimientos-farmaceuticos.htmlhttp://es.slideshare.net/MelisaBuritica/calidad-de-salud-en-colombia-16723108http://es.slideshare.net/MelisaBuritica/calidad-de-salud-en-colombia-16723108http://es.slideshare.net/Javesal/origenes-de-lafarmaciahttp://es.wikipedia.org/wiki/Farmaciahttps://www.minsalud.gov.co/Normatividad_Nuevo/RESOLUCION%201403%20DE%202007.pdfhttps://www.minsalud.gov.co/Normatividad_Nuevo/RESOLUCION%201403%20DE%202007.pdfhttp://legislacionfarmaceutica.blogspot.com/2008/05/establecimientos-farmaceuticos.htmlhttp://legislacionfarmaceutica.blogspot.com/2008/05/establecimientos-farmaceuticos.html


38/39

>))K('.'-+.-&/&-"!176308-&-()&(*/*-*Z'-+

>))K.,*)*'/(-*,*/*-&?&'*.-&/)(/*'/C3A")&&'(

()*--C3B34'C3B3 >))K.(-&('(.-&/D(-&(+&)-*.> >))K*'('**/*-*.+,&?'&).-&/200"07)/

GLOSARIO

ATENCION FARMACEUTICAKE' ,* *'')(-* * 4 *-()( & ?4&' ( *-()(':

& *)( (, $4=/-& F*/*-4)-&: ( (, '(?4/()& (, )*)*/()& 5/*-&

)(*4)-&: ?* * -&)+4 -& (, /-& )*)*)( ; &)&' &('&*,(' (, 5(*

( ,* '*,4 ( ,* -&'(-4-9 ( ,&' ('4,)*&' (')&' ** /(&* '4 -*,* (

*.

ENFERMEDADA,)(*-9 /5' & /(&' ?*( ( ,* '*,4

MEDICAMENTOE' (, 5/*-&


39/39

SERVICIO FARMACEUTICO (' (, '(-& ( *)(-9 ( '*,4 ('&'*+,( (

,*' *-)*(' ( &4--9: *,/*-(*/()&: ')+4-9: -&/(-*,*-9:'('*-9: -&)&, & *'(?4*/()& ( ,* -*,* ( ,&' /(-*/()&' ; ,&'

'&')&' /-&' 4),*&' ( ,* &/&-9 ( ,* '*,4 ; ,* ((-9

*?9')-&: )*)*/()& ; (>*+,)*-9 ( ,*' ((/(*('.

ESTABLECIMIENTO FARMACEUTICO '( -&'(* (')*+,(-/()& */*-4)-&

* )&& (')*+,(-/()& (-*& * ,* &4--9: *,/*-(*/()&: ')+4-9

-&/(-*,*-9: '('*-9: -&)&, & *'(?4*/()& ( ,* -*,* ( ,&'/(-*/()&': '&')&' /-&' & ( ,*' /*)(*' /*' (-('**' ** '4

(,*+&*-9 ; (/5' &4-)&' *4)&*&' & ,* ,(; ** ,* -&/(-*,*-9

(->& (')*+,(-/()&.

Francia Cabrera y Equipo

Documents

Transcript of Francia Cabrera y Equipo